Close

BioNTech SE (BNTX) and Pfizer (PFE) Submit FDA Application for EMA of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children Aged 5-11

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. IBM
8. V
9. KMB
10. MSCI


Go back to BioNTech SE (BNTX) and Pfizer (PFE) Submit FDA Application for EMA of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children Aged 5-11

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

September 26, 2022 6:45 AM EDT

NEW YORK and MAINZ, GERMANY, September 26, 2022 Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use... More